The Peyronie’s disease treatment market is growing steadily, driven by increasing awareness of the condition and advancements in medical technologies. Peyronie’s disease (PD) is a connective tissue disorder characterized by the formation of fibrous plaques in the penis, leading to curvature, pain, and potential erectile dysfunction. It is estimated to affect approximately 1 in 10 men, particularly in middle and older age groups, making it a significant men’s health issue. Recent advancements have improved treatment options, ranging from minimally invasive therapies to advanced surgical procedures. For instance, collagenase clostridium histolyticum (XIAFLEX) remains the only FDA-approved nonsurgical treatment, offering patients a targeted, effective approach to manage plaque and penile curvature. The integration of digital health tools, such as self-assessment apps and telemedicine platforms, has further enhanced patient engagement and access to care. In addition, innovations such as shockwave therapy and next-generation devices such as VerticaPlus, which combine treatment with cloud-based mobile applications for personalized feedback, represent a shift towards patient-centric solutions. As awareness campaigns and product launches increase, the Peyronie’s disease treatment market is expected to witness robust growth, benefiting both patients and healthcare providers.
